BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.39, $0.60 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $227.9 million versus the consensus estimate of $224.38 million.

GUIDANCE:

BioMarin Pharma sees FY2016 revenue of $1.05-1.10 billion, versus the consensus of $1.15 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.